Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
---|---|---|---|---|---|
BIOSIG TECHNOLOGIES Aktie jetzt für 0€ handeln | |||||
03.03. | BioSig Technologies, Inc. - 8-K, Current Report | - | SEC Filings | ||
13.01. | BioSig Technologies, Inc. - S-8, Securities to be offered to employees in employee benefit plans | - | SEC Filings | ||
31.12.24 | BioSig Technologies, Inc. - 8-K, Current Report | - | SEC Filings | ||
18.12.24 | BioSig Technologies, Inc. - 8-K, Current Report | - | SEC Filings | ||
06.12.24 | BioSig Technologies, Inc. - 8-K, Current Report | - | SEC Filings | ||
14.11.24 | BioSig Technologies, Inc. - 10-Q, Quarterly Report | - | SEC Filings | ||
13.11.24 | BioSig Technologies, Inc.: BioSig Regains Compliance with Nasdaq's Minimum Bid Price Requirement | 75 | GlobeNewswire (Europe) | Los Angeles, CA, Nov. 13, 2024 (GLOBE NEWSWIRE) -- BioSig Technologies, Inc. (NASDAQ: BSGM) ("BioSig" or "Company"), a medical technology company delivering unprecedented accuracy and precision to... ► Artikel lesen | |
13.11.24 | BioSig Technologies, Inc. - 8-K, Current Report | - | SEC Filings | ||
29.10.24 | BioSig Faces NASDAQ Delisting Over Price Deficiency | 1 | Investing.com | ||
29.10.24 | BioSig droht Delisting von der NASDAQ aufgrund zu niedriger Aktienkurse | 1 | Investing.com Deutsch | ||
29.10.24 | BioSig Technologies, Inc. - 8-K, Current Report | 2 | SEC Filings | ||
22.10.24 | BioSig Technologies, Inc.: BioSig Technologies' Common Stock to Resume Trading on the NASDAQ Exchange, Wednesday, October 23, 2024 After Its Successful Appeal to the NASDAQ Panel | 98 | GlobeNewswire (Europe) | Los Angeles, CA, Oct. 22, 2024 (GLOBE NEWSWIRE) -- BioSig Technologies, Inc. (OTCQB: BSGM) ("BioSig" or the "Company"), a medical technology company delivering unprecedented accuracy and precision... ► Artikel lesen | |
22.10.24 | BioSig granted grace period to meet Nasdaq listing requirements | 1 | Investing.com | ||
22.10.24 | BioSig erhält Gnadenfrist zur Erfüllung der Nasdaq-Notierungsanforderungen | 1 | Investing.com Deutsch | ||
22.10.24 | BioSig Technologies, Inc. - 8-K, Current Report | 1 | SEC Filings | ||
31.07.24 | BioSig Technologies, Inc.: BioSig Technologies Announces Intent to Acquire the Assets of Neuro-Kinesis Corporation | 159 | GlobeNewswire (Europe) | Los Angeles, July 31, 2024 (GLOBE NEWSWIRE) -- BioSig Technologies, Inc. (OTCQB: BSGM) ("BioSig" or "Company"), a medical technology company delivering unprecedented accuracy and precision to intra-cardiac... ► Artikel lesen | |
25.07.24 | BioSig Technologies, Inc.: BioSig Technologies Improves Balance Sheet, Announces Reduction in Outstanding Payables during Q2 2024 | 112 | GlobeNewswire (Europe) | Los Angeles, CA 90025, July 25, 2024 (GLOBE NEWSWIRE) -- BioSig Technologies, Inc. (OTCQB: BSGM) or ("BioSig" or "Company"), a medical technology company delivering unprecedented accuracy and precision... ► Artikel lesen | |
10.06.24 | BioSig Technologies, Inc.: BioSig Technologies Appoints Mr. Ferdinand Groenewald to Position of Interim Chief Financial Officer and Principal Accounting Officer | 159 | GlobeNewswire (Europe) | Westport, CT, June 10, 2024 (GLOBE NEWSWIRE) -- BioSig Technologies, Inc. (NASDAQ: BSGM) or ("BioSig" or "Company"), a medical technology company delivering unprecedented accuracy and precision to... ► Artikel lesen | |
21.05.24 | BioSig Technologies, Inc.: BioSig Technologies Chief Executive Officer Mr. Anthony Amato Issues the Following Letter to Shareholders | 206 | GlobeNewswire (Europe) | Westport, CT, May 21, 2024 (GLOBE NEWSWIRE) -- BioSig Technologies, Inc. (Nasdaq: BSGM) ("BioSig" or "Company"), a medical technology company delivering unprecedented accuracy and precision to intra-cardiac... ► Artikel lesen | |
03.05.24 | BioSig Technologies, Inc. Announces New Appointments to its Now Fully Constituted Board of Directors, which is Comprised of 5 Board Members, 3 Independent | 129 | GlobeNewswire (Europe) | Westport, CT, May 03, 2024 (GLOBE NEWSWIRE) -- BioSig Technologies, Inc. (NASDAQ: BSGM) or ("BioSig" or "the Company"), a medical technology company delivering unprecedented accuracy and precision... ► Artikel lesen |
Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
---|---|---|---|---|---|
SERNOVA BIOTHERAPEUTICS | 0,111 | -4,79 % | Sernova Aktie: Positives Umsatzwachstum gemeldet! | Das Biotechnologieunternehmen erweitert sein Führungsteam, sichert Finanzierungen und erhält FDA-Freigabe für klinische Studien zur Behandlung von Hypothyreose. Sernova Biotherapeutics, ehemals Sernova... ► Artikel lesen | |
ATOSSA THERAPEUTICS | 0,680 | +1,95 % | Atossa Therapeutics, Inc.: Atossa Therapeutics Announces Plans to Pursue Metastatic Breast Cancer Indication for (Z)-Endoxifen and Continued Engagement with FDA on Additional Indications | SEATTLE, March 11, 2025 (GLOBE NEWSWIRE) -- Atossa Therapeutics, Inc. (Nasdaq: ATOS) ("Atossa" or the "Company"), a clinical-stage biopharmaceutical company dedicated to the prevention and treatment... ► Artikel lesen | |
PING AN HEALTHCARE | 0,889 | 0,00 % | Ping An Healthcare and Technology Company Limited: Ping An Health Reports First Full-Year Profit in 2024 | Synergies Between Health Care and Insurance Drive Scalable GrowthAI Innovations Fuel Continued Success
SHANGHAI and HONG KONG, March 13, 2025 /PRNewswire/ -- Ping An Healthcare and Technology... ► Artikel lesen | |
MOUNTAIN VALLEY MD | 0,012 | -32,58 % | Mountain Valley MD Holdings Inc: Mountain Valley hopes for continued growth in 2025 | ||
CO-DIAGNOSTICS | 0,392 | -3,45 % | Co-Diagnostics, Inc. Announces Intention to Submit Enhanced Version of COVID-19 Test to FDA for 510(k) Clearance | The Company is withdrawing current submission based on FDA feedback related to shelf-life stability of a test component
SALT LAKE CITY, Feb. 21, 2025 /PRNewswire/... ► Artikel lesen | |
CYTOSORBENTS | 0,976 | -5,79 % | CytoSorbents Reports Preliminary Unaudited Fourth Quarter and Full-Year 2024 Product Revenue | Fourth quarter product revenue growth estimated at 22% to 25% year-over-year Fourth quarter gross margin estimated to improve to approximately 70% Management will host in-person investor... ► Artikel lesen | |
VERU | 0,473 | +3,63 % | VERU INC. - 8-K, Current Report | ||
TEMPEST THERAPEUTICS | 0,780 | +0,13 % | Tempest Therapeutics: FDA Study May Proceed Notice Received for Phase 2 Trial of TPST-1495 for the Treatment of Familial Adenomatous Polyposis (FAP) | BRISBANE, Calif., March 13, 2025 (GLOBE NEWSWIRE) -- Tempest Therapeutics, Inc. (Nasdaq: TPST), a clinical-stage biotechnology company developing first-in-class1 targeted and immune-mediated therapeutics... ► Artikel lesen | |
VOLITIONRX | 0,552 | 0,00 % | VolitionRx erweitert Krebstest-Vereinbarung mit Fujifilm Vet Systems | ||
EKSO BIONICS | 0,445 | +9,34 % | Ekso Bionics Holdings, Inc.: Ekso Bionics Reports Fourth Quarter and Full-Year 2024 Financial Results | SAN RAFAEL, Calif., March 03, 2025 (GLOBE NEWSWIRE) -- Ekso Bionics Holdings, Inc. (Nasdaq: EKSO) ("Ekso Bionics" or the "Company"), an industry leader in exoskeleton technology for medical and industrial... ► Artikel lesen | |
IMUNON | 0,795 | +4,61 % | Imunon, Inc.: IMUNON Reports 2024 Financial Results and Provides Business Update Highlighting Significant Progress Towards the Initiation of a Pivotal Phase 3 Study | IMNN-001 remains the first immunotherapy to achieve a meaningful overall survival benefit in advanced ovarian cancer Patient enrollment in Phase 3 pivotal trial of IMNN-001 scheduled to begin in... ► Artikel lesen | |
BEYOND AIR | 0,278 | +0,72 % | Beyond Air-Direktor Robert Carey kauft Stammaktien im Wert von 250.050 US-Dollar | ||
AVINGER | 0,340 | -6,08 % | Avinger, Inc.: Avinger Reports Third Quarter 2024 Results | Lower Operating Cost Profile Drives Improved Productivity, Increased Gross Margin REDWOOD CITY, CA / ACCESSWIRE / November 7, 2024 / Avinger, Inc. (Nasdaq:AVGR), a commercial-stage medical device company... ► Artikel lesen | |
GERRESHEIMER | 80,05 | -0,19 % | Kreise: Warburg und KKR haben bei Ringen um Gerresheimer die Nase vorne | LONDON (dpa-AFX) - Beim Ringen um die mögliche Übernahme des Pharma- und Kosmetikverpackungsherstellers Gerresheimer hat offenbar ein Konsortium um die Beteiligungsgesellschaften Warburg Pincus und... ► Artikel lesen | |
CARL ZEISS MEDITEC | 69,65 | +4,82 % | GOLDMAN SACHS stuft CARL ZEISS MEDITEC AG auf 'Buy' | NEW YORK (dpa-AFX Analyser) - Die US-Investmentbank Goldman Sachs hat Carl Zeiss Meditec von "Neutral" auf "Buy" hochgestuft und das Kursziel von 59 auf 74 Euro angehoben. Anzeichen für eine Stabilisierung... ► Artikel lesen |